The presence of CH did not affect the risk of death in anemic individuals.7 Furthermore, it has been shown that the presence of CH in patients with chronic idiopathic neutropenia did not significantly correlate with the severity of neutropenia but mutations in SRSF2 and IDH1 were associated with malignant transformation.22 Recently, it was shown in a clinical cohort of cases with primary immune thrombocytopenia (ITP, n = 14) that the presence of CH in ITP patients was closely related to disease severity and treatment responsiveness. The gene discussed is SRSF2; the disease is cyclic hematopoiesis.